Axsome Therapeutics Joins the Global Narcolepsy Community in Raising Awareness on World Narcolepsy Day
September 21, 2023 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...
Axsome Therapeutics Highlights Commitment to Innovating Treatments for Mental Health Conditions with Presentations at Psych Congress 2023
September 07, 2023 07:03 ET
|
Axsome Therapeutics, Inc.
Data presentations explore effects on patient-centric efficacy measures of treatments for patients with depression, and excessive sleepiness associated with obstructive sleep apnea and narcolepsy NEW...
Sleep Tech Devices Market revenue to reach USD 50 Billion by 2035, says Research Nester
August 10, 2023 07:00 ET
|
Research Nester
New York, Aug. 10, 2023 (GLOBE NEWSWIRE) -- The global sleep tech devices market size is slated to expand at ~15% CAGR between 2023 and 2035. The market is poised to garner a revenue of USD 50...
Wake Up Narcolepsy Debuts Public Service Announcement in Collaboration with Red Square Pictures
July 11, 2023 11:17 ET
|
Wake Up Narcolepsy
WORCESTER, Mass., July 11, 2023 (GLOBE NEWSWIRE) -- Wake Up Narcolepsy (WUN), a national leader for research and awareness, premiered its Narcolepsy public service announcement in partnership with Red...
Ambulatory Polysomnography (PSG) Systems Market to Garner $570.7 Million by 2031 with 6.0% CAGR | Research Dive
June 14, 2023 09:00 ET
|
Research Dive
New York, USA, June 14, 2023 (GLOBE NEWSWIRE) -- According to a report published by Research Dive, the global ambulatory polysomnography (PSG) systems market is projected to generate a revenue of...
Axsome Therapeutics to Present Data and Post-Hoc Analyses on Auvelity® and Sunosi® at the 2023 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting
May 30, 2023 07:00 ET
|
Axsome Therapeutics, Inc.
Data on Auvelity demonstrating improved functioning in major depressive disorder Data on Sunosi demonstrating improved cognitive function in patients with excessive daytime sleepiness associated with...
Axsome Therapeutics to Present Five Abstracts Including New Data from the Positive SHARP Study of SUNOSI® (solriamfetol) in Participants with Cognitive Impairment with Excessive Daytime Sleepiness in Obstructive Sleep Apnea at the 2023 American Academy of Neurology (AAN) Annual Meeting
April 21, 2023 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, April 21, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...
Axsome Therapeutics Enters into License Agreement with Pharmanovia to Expand Commercialization and Further Develop Sunosi® (solriamfetol) in Europe
February 22, 2023 07:00 ET
|
Axsome Therapeutics, Inc.
Axsome to receive an upfront payment of $66 million, and is eligible to receive sales-based and other milestones totaling up to $101 million Pharmanovia is responsible for all ongoing and future...
Vallon Pharmaceuticals Reports Third Quarter 2022 Financial Results
November 03, 2022 16:30 ET
|
Vallon Pharmaceuticals Inc.
PHILADELPHIA, PA, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the...
Axsome Therapeutics Announces Publication of Post-hoc Analysis of Sunosi® Effect on Excessive Daytime Sleepiness in Narcolepsy or Obstructive Sleep Apnea Patients with a History of Depression in the Journal of Psychiatric Research
September 07, 2022 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...